C&EN White Paper
A need for speed: How the new pharma is accelerating the bench to bedside timeline
Brought to you by Spectrum Chemical Mfg. Corp.

The COVID-19 pandemic showed the world that when it comes to pharmaceuticals, fast is achievable. Traditional models for drug development, manufacture, approval, and launch were upended. Timelines were shrunk and processes streamlined; existing drugs were repurposed, and the launch of novel ones accelerated. Bold new approaches led to countless lives being saved. Now, drug researchers and developers, manufacturers, and raw material suppliers are applying lessons learned to accelerating the future of pharma. This radical rethink will not only support future pandemic preparedness, but it will also revolutionize how pharmaceuticals targeting other diseases are developed and manufactured.

Key Objectives:
  • The COVID-19 pandemic demonstrated that fast pharma is achievable, and lessons learned are revolutionizing the industry.
  • Drug development, clinical trial, manufacturing, and approval timelines can be dramatically reduced.
  • Repurposing existing drugs and fast-forwarding the development of new ones plays a critical role in speeding up processes.
  • Streamlining supply chains and using pretested raw materials will support accelerated pharmaceutical timelines.
  • When researchers, manufacturers, suppliers of chemicals and other stakeholders collaborate, lives can be saved.

Brought to you by:
Spectrum Chemical Mfg. Corp.
Please complete the form to download the white paper.
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy .

Copyright © 2024 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy